Phase I Study of Radiation Therapy With Concurrent Sorafenib for Hepatocellular Carcinoma Not Responding to Transarterial Chemoembolization

Trial Profile

Phase I Study of Radiation Therapy With Concurrent Sorafenib for Hepatocellular Carcinoma Not Responding to Transarterial Chemoembolization

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Sep 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 31 Jul 2012 Actual initiation date (1 Jun 2012) added as reported by ClinicalTrials.gov record.
    • 31 Jul 2012 Planned number of patients (30) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top